These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 27001804)

  • 1. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
    Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
    McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M
    Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
    Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
    Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
    Taylor DN; Tacket CO; Losonsky G; Castro O; Gutierrez J; Meza R; Nataro JP; Kaper JB; Wasserman SS; Edelman R; Levine MM; Cryz SJ
    Infect Immun; 1997 Sep; 65(9):3852-6. PubMed ID: 9284163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
    Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL
    Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
    Sow SO; Tapia MD; Chen WH; Haidara FC; Kotloff KL; Pasetti MF; Blackwelder WC; Traoré A; Tamboura B; Doumbia M; Diallo F; Coulibaly F; Onwuchekwa U; Kodio M; Tennant SM; Reymann M; Lam DF; Gurwith M; Lock M; Yonker T; Smith J; Simon JK; Levine MM
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.
    Cohen MB; Giannella RA; Bean J; Taylor DN; Parker S; Hoeper A; Wowk S; Hawkins J; Kochi SK; Schiff G; Killeen KP
    Infect Immun; 2002 Apr; 70(4):1965-70. PubMed ID: 11895960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection.
    Haney DJ; Lock MD; Gurwith M; Simon JK; Ishioka G; Cohen MB; Kirkpatrick BD; Lyon CE; Chen WH; Sztein MB; Levine MM; Harris JB
    Vaccine; 2018 May; 36(20):2768-2773. PubMed ID: 29655627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111.
    Tacket CO; Kotloff KL; Losonsky G; Nataro JP; Michalski J; Kaper JB; Edelman R; Levine MM
    Am J Trop Med Hyg; 1997 May; 56(5):533-7. PubMed ID: 9180604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.
    Chen WH; Greenberg RN; Pasetti MF; Livio S; Lock M; Gurwith M; Levine MM
    Clin Vaccine Immunol; 2014 Jan; 21(1):66-73. PubMed ID: 24173028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine.
    Jackson SS; Chen WH
    Future Microbiol; 2015; 10(8):1271-81. PubMed ID: 26228388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
    Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
    Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial.
    McCarty JM; Lock MD; Bennett S; Hunt KM; Simon JK; Gurwith M
    Vaccine; 2019 Mar; 37(11):1389-1397. PubMed ID: 30772070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
    Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
    Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years.
    McCarty JM; Gierman EC; Bedell L; Lock MD; Bennett S
    Am J Trop Med Hyg; 2020 Jan; 102(1):48-57. PubMed ID: 31769402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.